Bulletin
Investor Alert

New York Markets Open in:

Oct. 15, 2021, 7:45 a.m. EDT

Why a pill you take at home could change the direction of the pandemic

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Merck & Co. Inc. (MRK)
  • X
    Eli Lilly & Co. (LLY)
  • X
    Regeneron Pharmaceuticals Inc. (REGN)

or Cancel Already have a watchlist? Log In

Jaimy Lee

Merck and Ridgeback Biotherapeutics’ promising oral antiviral could shift the direction of the pandemic by making it easier for people with COVID-19 to take a pill at home that can keep them from getting severely sick.

Merck’s /zigman2/quotes/209956077/composite MRK -1.55% stock gained 9.1% in trading on Friday after announcing that the drug, molnupiravir, cut the risk of hospitalization or death by 50% in a Phase 3 clinical trial. (Ridgeback is privately held.)

The drug, which inhibits replication of the virus, was tested in 775 “at-risk” adults with mild or moderate cases of COVID-19. No one taking the drug died in the trial; eight deaths were reported among those taking the placebo.

It also appeared to work against the gamma, delta, and mu variants in the roughly 40% of participants for whom sequencing was available. 

“It’s a very big deal,” Dr. Eric Topol, director of the Scripps Research Translational Institute, said in an email. “If safe and inexpensive (even freely available) as a pill that is easily taken, it could have enormous benefit for reducing severe illness, for both unvaccinated and breakthrough vaccinated people.”

Topol on Twitter has already referred to molnupiravir as the “M-pack,” a play on the commonly prescribed Z-Pack antibiotics.

The U.S. has already ordered 1.7 million treatment courses of molnupiravir at a price of about $705 for each five-day course of treatment.

That said, there are still a few caveats. The companies have so far only shared clinical data in a news release and not in a preprint or medical study. It’s also unclear if any of the participants in the trial were vaccinated and if so, how many. (Topol noted that knowing this won’t “detract from its potential importance.”)

The case for new COVID-19 treatments

The COVID-19 vaccines are by far the best therapeutic tool in our pandemic arsenal. Not only are they very effective at preventing people from ending up in the hospital or dying, they for the most part keep people from getting even mild cases of COVID-19, though these breakthrough infections are on the rise.

There are a handful of therapies that can help COVID-19 patients who are at high risk of developing severe cases or are already in the hospital, but all of them are administered by infusion in a healthcare setting.

These include the monoclonal antibodies developed by Eli Lilly & Co. /zigman2/quotes/200106384/composite LLY -0.50% , Regeneron Pharmaceuticals Inc. /zigman2/quotes/203149337/composite REGN +1.61% , and Vir Biotechnology Inc. /zigman2/quotes/214486077/composite VIR +11.96% and GlaxoSmithKline /zigman2/quotes/209463850/composite GSK +1.48% . Other therapies, like Gilead Sciences Inc.’s /zigman2/quotes/210293917/composite GILD +0.22% Veklury and the steroid dexamethasone, which has been repurposed as a COVID-19 drug, are reserved for critically ill hospitalized patients.

When it comes to treatments for mild to moderate cases of COVID-19 among the general public, we have been out of luck. There are no Tamiflu-like pills that patients can take at home. 

“The availability of an effective oral drug that can be given in the outpatient setting can blunt the risks associated with breakthrough infections and reduce mortality in the unvaccinated, which can begin to move the nation out of the pandemic and hasten reopening,” RBC Capital Markets analyst Brian Abrahams told investors on Friday.

If and when authorization or approval of molnupiravir and other investigational antivirals takes place, it will likely shift the course of the pandemic and bring us one step closer to making the virus something we can live with and less of something to be feared.

“The fact that this is moving from a pandemic probably to being more endemic, there’s a real need for an antiviral,” Merck CEO Robert Davis said Sept. 13 at the Morgan Stanley Global Healthcare Conference, according to a FactSet transcript of the presentation.

Other COVID-19 antivirals in development

There are half a dozen oral antiviral drugs in development right now, spurred by a $3 billion investment from the National Institutes of Health into COVID-19 antiviral development back in June. 

Pfizer Inc. /zigman2/quotes/202877789/composite PFE +0.47% , already a pandemic favorite for its role developing Comirnaty, the first authorized and approved COVID-19 vaccine in the U.S., is expected to have late-stage clinical data for its investigational antiviral pill before the end of the year.

“We think an oral is a critical piece of the solution to the pandemic,” Pfizer Chief Financial Officer Frank D’Amelio said Sept. 14 at a Morgan Stanley conference. “It could be prescribed for a 5-day treatment course at the first sign of infection before patients are hospitalized for critical care.”

Both Pfizer and Merck are also testing their antivirals for post-exposure prophylaxis to COVID-19. In these instances, if someone is exposed to another person who has tested positive for the virus, they can take medication preventively to ward off a COVID-19 infection. 

Several other small drug makers and biotechs are also testing antivirals as COVID-19 treatments, including Adamis Pharmaceuticals Corp. /zigman2/quotes/205166351/composite ADMP +3.36% , Atea Pharmaceuticals Inc. /zigman2/quotes/222210381/composite AVIR +6.31% , and RedHill Biopharma Ltd. /zigman2/quotes/209675411/composite RDHL +11.70% . Gilead has also been studying Veklury as a treatment for high-risk COVID-19 patients who have not been hospitalized.

Merck said Friday it plans to soon submit the data for emergency authorization.

Merck’s stock is down 3.7% for the year, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX +2.07% is up 14.7%.

/zigman2/quotes/209956077/composite
US : U.S.: NYSE
$ 72.28
-1.14 -1.55%
Volume: 17.64M
Dec. 7, 2021 4:02p
P/E Ratio
25.52
Dividend Yield
3.82%
Market Cap
$185.45 billion
Rev. per Employee
$648,824
loading...
/zigman2/quotes/200106384/composite
US : U.S.: NYSE
$ 245.11
-1.22 -0.50%
Volume: 4.04M
Dec. 7, 2021 4:02p
P/E Ratio
37.42
Dividend Yield
1.39%
Market Cap
$235.64 billion
Rev. per Employee
$701,137
loading...
/zigman2/quotes/203149337/composite
US : U.S.: Nasdaq
$ 635.09
+10.09 +1.61%
Volume: 652,554
Dec. 7, 2021 4:00p
P/E Ratio
10.14
Dividend Yield
N/A
Market Cap
$67.23 billion
Rev. per Employee
$931,393
loading...
/zigman2/quotes/214486077/composite
US : U.S.: Nasdaq
$ 42.98
+4.59 +11.96%
Volume: 1.86M
Dec. 7, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$5.02 billion
Rev. per Employee
$233,541
loading...
/zigman2/quotes/209463850/composite
US : U.S.: NYSE
$ 42.38
+0.62 +1.48%
Volume: 5.51M
Dec. 7, 2021 4:00p
P/E Ratio
18.04
Dividend Yield
4.72%
Market Cap
$95.75 billion
Rev. per Employee
$464,855
loading...
/zigman2/quotes/210293917/composite
US : U.S.: Nasdaq
$ 69.65
+0.15 +0.22%
Volume: 6.44M
Dec. 7, 2021 4:00p
P/E Ratio
11.88
Dividend Yield
4.08%
Market Cap
$87.18 billion
Rev. per Employee
$1.81M
loading...
/zigman2/quotes/202877789/composite
US : U.S.: NYSE
$ 51.72
+0.24 +0.47%
Volume: 41.58M
Dec. 7, 2021 4:02p
P/E Ratio
15.35
Dividend Yield
3.02%
Market Cap
$288.95 billion
Rev. per Employee
$533,860
loading...
/zigman2/quotes/205166351/composite
US : U.S.: Nasdaq
$ 0.71
+0.02 +3.36%
Volume: 1.29M
Dec. 7, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$102.75 million
Rev. per Employee
$142,478
loading...
/zigman2/quotes/222210381/composite
US : U.S.: Nasdaq
$ 8.25
+0.49 +6.31%
Volume: 2.51M
Dec. 7, 2021 4:00p
P/E Ratio
30.30
Dividend Yield
N/A
Market Cap
$644.88 million
Rev. per Employee
$1.25M
loading...
/zigman2/quotes/209675411/composite
US : U.S.: Nasdaq
$ 2.96
+0.31 +11.70%
Volume: 870,931
Dec. 7, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$146.72 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,686.75
+95.08 +2.07%
Volume: 2.48B
Dec. 7, 2021 5:05p
loading...

Get news alerts on Merck & Co. Inc. — or create your own.
This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.